Navigation

Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus

Bevacizumab, sorafenib, sunitinib and temsirolimus for renal cell carcinoma

Status: History
Expected date of issue: June 2009
Referral date: June 2007
Process: MTA
Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Rebecca Trowman
Communications manager: Sarita Tamber
Project manager: Laura Malone
Assessment Group / Evidence Review Group: Peninsula Technology Assessment Group, University of Exeter
Top


 

Provisional schedule

Consultation on draft scope by stakeholders: August 2007
Final scope published: October 2007
1st appraisal committee meeting: 09 July 2008
2nd appraisal committee meeting: 10 September 2008
3rd appraisal committee meeting: 14 January 2009
4th appraisal committee meeting: 11 March 2009
Top


 

Consultees and commentators

Consultees Commentators (no right of appeal)

Manufacturers / Sponsors

  • Bayer plc (sorafenib)
  • Pfizer Ltd (sunitinib)
  • Roche Products Limited (bevacizumab)
  • Wyeth Pharmaceuticals (temsirolimus)

Patient / Carer Groups

  • Cancerbackup
  • James Whale Fund for Kidney Cancer
  • Kidney Cancer UK
  • Kidney Research UK
  • National Kidney Federation
  • Rarer Cancers Forum
  • South Asian Health Foundation

Professional Groups

  • British Uro-oncology Group
  • Cancer Network
  • Pharmacists Forum
  • Cancer Research UK
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians, Medical Oncology Joint Special Committee

Others

  • Cambridgeshire PCT
  • Department of Health
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator Manufacturers

  • Novartis Pharmaceuticals Ltd (interleukin-2)
  • Roche Products Ltd (interferon alpha)

Assessment Team

  • Peninsula Technology Assessment Group, University of Exeter
  • National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme)

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Research Groups

  • MRC Clinical Trials Unit

Top


 

Project history

Date Update
10 January 2008 Schedule and stakeholder list updated.
18 April 2008 NICE project team, schedule and stakeholders updated.
13 May 2008 Schedule updated
17 November 2008

The Appraisal Committee met in September 2008 to discuss Bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma.

During consultation on the Assessment Report and Appraisal Consultation Document (ACD), new data for a subgroup of patients was received from the marketing authorisation holder of sunitinib.  As a result of these submissions, and the response to the ACD by the marketing authorisation holder of bevacizumab, the Institute has commissioned further critical review of the evidence base.

In accordance with our published process, registered consultees and commentators have been given the opportunity to consult on the new evidence and the results of the critical review before convening a final meeting of the Appraisal Committee, which will now take place on 14 January 2009.

6 February 2009 The guidance on first line use of sunitinib has been developed on the understanding that the currently available treatment for advanced and/or metastatic renal cell carcinoma is immunotherapy (namely interferon-alfa and interleukin-2). The Institute recognises that there are people who have had or who are currently receiving immunotherapy and wish to clarify the implications of the guidance for these people. Sunitinib can be considered as a treatment option for those people with advanced and/or metastatic RCC who are currently receiving immunotherapy or who have had immunotherapy before the release of our final recommendations to ensure they are not disadvantaged by our proposed guidance.
Top


 

Key documents

This page was last updated: 30 March 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.